Precision Pathways: The 2026 Strategic Evolution of the Migraine Medication Market
As of early 2026, the global migraine medication market has shifted from a reactive, analgesic-heavy sector to a proactive, precision-driven vertical. This industry is currently undergoing a systemic transformation, characterized by a move away from legacy therapies—such as triptans and ergotamines—toward high-affinity CGRP (Calcitonin Gene-Related Peptide) inhibitors and innovative small molecule gepants. For B2B stakeholders, … Read more